Please assess the completion status of the following clinical trial:

Trial Title: Controlled Trial: 5-day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria were:~* Adults aged 18 years or older~* A fever of higher than 37.5°C~* The concurrent presence of eschar or a maculopapular skin rash; and the clear presence of more than two symptoms such as headache, malaise, myalgia, coughing, nausea and abdominal discomfort.~* Patients were hospitalized at Chosun University Hospital in Kwangju, Korea or one of its two community-based affiliated hospitals which are all located in southwestern Korea between 2006 and 2009.~Exclusion Criteria:~The exclusion criteria were:~* An inability to take oral medications~* Pregnancy~* Hypersensitivity to the trial drugs~* Previous drug therapy with potential antirickettsial activity (e.g., rifampicin, chloramphenicol, macrolides, fluoroquinolones or tetracyclines) within 48 h prior to admission~* Severe scrub typhus (shock requiring vasopressor therapy for more than one hour~* A stuporous or comatose level of consciousness~* Respiratory failure requiring mechanical ventilation or renal failure requiring immediate dialysis) (4, 10).~* For the differential diagnosis of scrub typhus from other diseases with similar symptoms (e.g., murine typhus, leptospirosis, hemorrhagic fever with renal syndrome and systemic lupus erythematosus), patients underwent diagnostic tests. We thus excluded patients with concurrent infections who had the risk of causing different outcomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): a 5-day course of daily 200-mg doses of doxycycline
- 2 (Type: ACTIVE_COMPARATOR): a 5-day course of daily 600-mg doses of rifampin

Based on this trial design, predict the completion outcome and termination type (if applicable).